Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Aisling Barry*, Smith Apisarnthanarax, Grainne M. O'Kane, Gonzalo Sapisochin, Robert Beecroft, Riad Salem, Sang Min Yoon, Young Suk Lim, John Bridgewater, Brian Davidson, Marta Scorsetti, Luigi Solbiati, Adam Diehl, Pablo Munoz Schuffenegger, Jonathan G. Sham, David Cavallucci, Zita Galvin, Laura A. Dawson, Maria A. Hawkins

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

Original languageEnglish (US)
Pages (from-to)765-775
Number of pages11
JournalThe Lancet Gastroenterology and Hepatology
Volume5
Issue number8
DOIs
StatePublished - Aug 2020

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective'. Together they form a unique fingerprint.

Cite this